IceCure Medical Ltd. — SEC Form D Filing

IceCure Medical Ltd. filed an SEC Form D on June 25, 2026, reporting $16.50M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
June 25, 2026
Amount reported
$16.50M
Round stage
Series B+
Industry
Medical Devices
Website
https://www.icecure-medical.com/

What the company does

Revenue: $1,000,001 - $5,000,000. Exemption: Rule 506(b). Incorporated: ISRAEL

Problem

Current treatments for breast cancer, such as surgery, often involve tissue removal, general anesthesia, and lengthy hospital stays, which can be daunting and invasive for patients.

Solution

IceCure Medical offers cryoablation using its ProSense® Cryoablation System, a minimally invasive treatment that freezes and destroys tumors without surgery, general anesthesia, or long hospital stays.

Why now

Advances in medical technology and increasing patient demand for less invasive treatment alternatives are driving the adoption of procedures like cryoablation.

Verdict

Investors funded this because it presented a clear alternative to a well-understood, high-cost procedure, not because it promised a novel therapeutic mechanism. The implicit bet was on a clear, direct cost-saving and patient experience improvement for a specific patient segment. This limited upside to adoption rates within existing clinical practice rather than market expansion, as the solution primarily optimizes an existing treatment path rather than creating a new one.

Source: SEC EDGAR Form D filing